These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33871787)
21. [Schnitzler syndrome: A dramatic improvement with anakinra]. Billey T; Beldjerd M; Popa L; Lassoued S Presse Med; 2010 Dec; 39(12):1338-9. PubMed ID: 20832239 [No Abstract] [Full Text] [Related]
22. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition. Jani P; Vissing MB; Ahmed S; Sluzevich JC; Aulakh S; Alegria V; Ailawadhi M; Chanan-Khan A; Ailawadhi S J Oncol Pract; 2018 Jun; 14(6):387-388. PubMed ID: 29558252 [No Abstract] [Full Text] [Related]
23. [Clonal-related transformation from Waldenström macroglobulinemia to diffuse large B cell lymphoma during the treatment of ibrutinib: a case report and literature review]. Xia Y; Zhu HY; Wang L; Chen RZ; Chen W; Ding CY; Xu W; Li JY Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):770-772. PubMed ID: 33113611 [No Abstract] [Full Text] [Related]
24. Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma. Yasuda H; Tsukune Y; Inano T; Mori Y; Ota Y; Komatsu N Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e176-e178. PubMed ID: 33127325 [No Abstract] [Full Text] [Related]
25. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Schuster C; Kränke B; Aberer E; Arbab E; Sturm G; Aberer W Int J Dermatol; 2009 Nov; 48(11):1190-4. PubMed ID: 20064173 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of anti-IL1 in Schnitzler's syndrome. Klemmer N; Lenain P; Balguerie X; Le Loët X Joint Bone Spine; 2007 Oct; 74(5):509-10. PubMed ID: 17921021 [No Abstract] [Full Text] [Related]
27. Complete Response of a Young Woman With MYD88 Pabon CM; Neff JL; Forns TE; Wang J Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904 [No Abstract] [Full Text] [Related]
29. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. de Koning HD; Schalkwijk J; van der Meer JW; Simon A J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363 [No Abstract] [Full Text] [Related]
30. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450 [TBL] [Abstract][Full Text] [Related]
31. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106 [TBL] [Abstract][Full Text] [Related]
32. Negative innovation: when patents are bad for patients. Feldman RC; Hyman DA; Price WN; Ratain MJ Nat Biotechnol; 2021 Aug; 39(8):914-916. PubMed ID: 34376839 [No Abstract] [Full Text] [Related]
33. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260 [No Abstract] [Full Text] [Related]
34. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. Krause K; Bonnekoh H; Ellrich A; Tsianakas A; Wagner N; Fischer J; Maurer M J Allergy Clin Immunol; 2020 Jun; 145(6):1681-1686.e5. PubMed ID: 31940469 [No Abstract] [Full Text] [Related]
35. Successful anakinra therapy in 2 patients with Schnitzler syndrome. Szturz P; Adam Z; Hájek R; Mayer J Onkologie; 2011; 34(5):265-8. PubMed ID: 21577034 [No Abstract] [Full Text] [Related]
36. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma. Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212 [TBL] [Abstract][Full Text] [Related]
37. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Jalink M; Berentsen S; Castillo JJ; Treon SP; Cruijsen M; Fattizzo B; Cassin R; Fotiou D; Kastritis E; De Haas M; Oosten LEM; Frederiksen H; Patriarca A; D'Sa S; Vos JMI Blood; 2021 Nov; 138(20):2002-2005. PubMed ID: 34293088 [No Abstract] [Full Text] [Related]
38. Anakinra: an effective treatment in the Schnitzler syndrome. Vandenhende MA; Bentaberry F; Morlat P; Bonnet F Joint Bone Spine; 2011 Dec; 78(6):636-7. PubMed ID: 21550281 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of Psoralen-UV-A therapy in 3 cases of Schnitzler syndrome. Cianchini G; Colonna L; Bergamo F; Angelo C; Puddu P Arch Dermatol; 2001 Nov; 137(11):1536-7. PubMed ID: 11708971 [No Abstract] [Full Text] [Related]
40. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. Schneider SW; Gaubitz M; Luger TA; Bonsmann G J Am Acad Dermatol; 2007 May; 56(5 Suppl):S120-2. PubMed ID: 17434038 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]